Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma

Huan Lu a,b,1, Dan-dan Ju c,1, Guang-dong Yang b,e,1, Lin-yan Zhu b, Xiao-mei Yang d, Jun Li d, Wei-wei Song b, Jin-hao Wang b, Can-can Zhang a,b, Zhi-gang Zhang d,*+, Rong Zhang a,b,⁎,+⁎

⁎⁎Corresponding author at: Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University, Shanghai 201499, China.
E-mail addresses: zhangle@shsci.org (Z. Zhang), rongzhang1985@163.com (R. Zhang).

1 Equal contributors.

1. Introduction

Endometrial cancer is the second most common gynecological malignancy among women worldwide with an estimated 61,380 new cases per year in the United States alone [1,2]. Recently, endometrial cancer was classified into four subtypes, POLE ultramutated, microsatellite instability hypermutated (MSI), copy number low, and copy number high, through an integrated analysis of genomic, transcriptomic, and proteomic characteristics of 373 endometrial carcinomas [3]. Among of the four subgroups, POLE proofreading mutant endometrial cancers have a favorable prognosis despite a strong association with high-grade cancer cells [4]. Patients with MSI tumors were more likely to present with early-stage disease [5,6]. Further, most endometrioid tumors have few somatic copy number alterations (SCNAS) when most
serous and serous-like tumors exhibit extensive SCNs with significantly worse progression-free survival than other groups [3]. Although most patients present with early-stage disease, 15–20% of these tumors still recur after primary surgery in metastatic disease [7,8], which require novel biomarkers or targets identified for diagnosing or treating.

The human endometrium is a highly regenerative tissue that undergoes a steroid-induced monthly cycle of proliferation, differentiation and shedding [9,10]. Evidence showed that endometrial stem cells were present in the endometrium and responsible for the cyclical regeneration of the endometrium each month [11]. The endometrium undergoes regenerative alterations under the influence of circulating ovarian steroid hormones, estrogen and progesterone [12]. CD15 appears to be a marker suitable for the enrichment of basal epithelial progenitor cells demonstrating classic adult stem cell properties [13]. Endometrial cancer was also confirmed to involve stem-like cells, self-renewing cancer stem cells (CSCs) [14]. These cells with stem cell properties are responsible for tumor growth and treatment resistance [15–17]. Furthermore, the vast majority of endometrial cancer is estrogen- and progesterone-related [18,19]. A variety of cell surface proteins have been successfully identified as surrogate markers for these cancer stem cells. In endometrial cancer, the surface markers, CD133 and CD44, have been used to enrich CSCs [20,21]. Recently, epithelial membrane protein-2 (EMP2) has been clearly demonstrated as an endometrial cancer stem cell-associated gene [22].

SPARC-related modular calcium binding 2 (SMOC-2), a member of the SPARC family, is highly expressed during embryogenesis and wound healing [23–25]. The gene product is a matricellular protein that can stimulate endothelial cell proliferation and migration, as well as angiogenic activity [24,26,27]. Furthermore, SMOC-2 has been identified as the intestinal stem cell signature gene that is required for L1-mediated colon cancer progression [28]. It has been suggested that SMOC-2 may mediate intercellular signaling and cell type-specific differentiation during gonad and reproductive tract development [23]. Thus, we wonder if SMOC-2 has similar characteristics in the CSCs of endometrial cancer.

In this study, we compared the CSCs (CD133+/CD44+) with non-CSCs (CD133−/CD44−) flow-sorted from endometrial cancer cells and found the expression of SMOC-2 was significantly higher in CD133+/CD44+ cells than in CD133−/CD44− cells. Silencing SMOC-2 suppressed the ability of the cells to form spheres and enhanced paclitaxel and cisplatin sensitivity in endometrial cancer cells. We further demonstrated that SMOC-2 physically interacted with Fzd6 and LRP6, enhanced their interaction with canonical Wnt ligands and thus activated the Wnt/β-catenin pathway in endometrial CSCs. Furthermore, SMOC-2 was high expression in endometrial cancer tissues and was closely associated with CSC markers expression in endometrial cancer tissue.

2. Materials and methods

2.1. Cell culture and reagents

Human endometrial cancer cells AN3CA, HEC-1A, ECC-1, Ishikawa and HEK293T were obtained as gifts from Shanghai Cancer Institute. All these cells were cultured according to American Type Culture Collection (ATCC) instructions. Antibodies used in this study were against SMOC-2 (ab70816, Abcam) for western blotting (WB) and Immunohistochemistry (IHC), CD133 (372805, Biolegend), CD44 (103008, Biolegend) for Flow Cytometry, CD133 (ab216323, Abcam), CD44 (ab51037, Abcam) and PCNA (13110, Cell Signaling) for IHC, β-actin (M1210–2, Huabio), β-Tubulin (66240–1-lg) and Lamin A/C (2032s, cell signaling) for western blotting (WB), β-catenin (ab32572, Abcam) for WB, immunofluorescence (IF), Wnt3a (ab28472, Abcam), Wnt10b (ab70816, Abcam), Frizzled3 (sc-68334, Santacruz), Frizzled6 (5158, cell signaling), Frizzled8 (sc-33503, Santacruz) Frizzled6 (5158, cell signaling), LRP1 (ab92544, Abcam), LRP6 (ab134146, Abcam), LRP7 (ab36121, Abcam), HA-tag (3724, cell signaling), Flag-tag (8146, cell signaling), and Myc-tag (2278, cell signaling) for CO-IP. Secondary antibodies were purchased from Jackson. TUNEL assay was purchased from Sigma (11684817910). Chemicals and biochemicals were Paclitaxel (EY1353, Amquar), cisplatin (EY0024, Amquar), FGF (091608, PeproTech), EGF (0816AF05, PeproTech), B27 (17504044, Gibco) and XAV-939 (S1180, Selleck).

2.2. Clinical samples

Human endometrial cancer and tissues normal endometrium were obtained from the Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University and the Department of Gynecology, Changzhou Maternal and Child Care Hospital. None of them had received radiotherapy, chemotherapy and other related anti-tumor therapies before surgery. All human tissues were obtained with informed consent and the study was approved by the Research Ethics Committee of Fengxian Hospital, Southern Medical University.

2.3. Immunohistochemical staining

Immunohistochemical staining were performed as described [29]. The following primary antibodies were used: SMOC-2 (1:200), CD133

Research in context

Evidence before this study

Endometrial cancer stem cells have been prospectively enriched by use of markers such as CD133, CD44 and ALDH. However, there is no conclusive evidence showing that none of these markers is the universal marker for endometrial cancer stem cells. Previously, SPARC-related modular calcium binding 2 (SMOC-2), an extracellular matrix proteins, has been found highly expressing during embryogenesis and wound healing. SMOC-2 mediated cell type-specific differentiation during gonad and reproductive tract development. It was also suggested as a stem cell signature gene in intestine.

Added value of this study

This study identifies SMOC-2 as a cancer stem cell signature gene in endometrial cancer. The expression of SMOC-2 was higher in CD133+/CD44+ cancer stem cells (CSCs) than in CD133−/CD44− non-CSCs. SMOC-2 expression is greatly increased in spheres compared to monolayer cultures. Using the sphere assay, silencing SMOC-2 reduced the clonogenic potential of endometrial cancer cells and downregulated the expression of SOX2, OCT4 and NANOG, the stemness-associated genes. SMOC-2 enhanced the chemoresistance of endometrial cancer cells. Immunohistochemical staining revealed that the expression of SMOC-2 was positively correlated with CSCs markers expression (CD133 and CD44) in patient tissues. Furthermore, we found that SMOC-2 activated WNT/β-catenin pathway through directly interacting with WNT receptors (Fzd6 and LRP6) in stem cells and enhanced the interaction between receptors (Fzd6 and LRP6) and WNT ligands (Wnt3a and Wnt10b).

Implication of all the available evidence

Together, SMOC-2 may be a signature gene for enrich endometrial cancer stem cells. SMOC-2-Wnt/β-catenin axis may play a crucial role in cell self-renewing and chemoresistance of endometrial CSCs. And SMOC-2-Wnt/β-catenin axis might be a novel target for endometrial cancer therapy.
expression of SOX2, OCT4, and NANOG in SMOC-2-overexpressioning cells HEC-1A/ECC-1 were detected by western blotting. SMOC-2-silenced cells AN3CA/Ishikawa were detected by western blotting. (i) Overexpression ef was shown. (mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test). (j) The expression of SOX2, OCT4, and NANOG in AN3CA, HEC-1A and ECC-1 cells were detected by western blotting. (k) Overexpression efficacy of SOX2 in HEC-1A and ECC-1 cells was determined by western blotting. The expression of SOX2, OCT4, and NANOG in SMOC-2-overexpressioning cells HEC-1A/ECC-1 were detected by western blotting.

2.4. Sphere formation assay

The spheres of endometrial cancer cells were cultured in DMEM: F12 medium containing 2% B27, 20 ng/ml bFGF, 20 ng/ml EGF and plated in 6-well Ultra-Low Attachment Plates. The growth factors were replenished every 3 days. 14-day-old spheres as primary sphere were harvested using 40 μm cell strainers, dissociated to single cells with trypsin, and then regrown for 7 days, defined as secondary sphere. The diameter and number (>50 μm) for primary and secondary spheres were evaluated and quantified [30].

2.5. Flow cytometry

Cell were prepared as single cell suspension for FACS staining. To identify endometrial CSCs, the following antibodies were used: FITC-CD133, PE-CD44 for 30 min at 4 °C and second antibody AF647 goat anti-mouse IgG for 30 min at 4 °C. The stained cells were acquired for analysis or sorting on LSRFortessa or Ariiell (BD). Flow cytometry data was analyzed with FlowJo software (Tree Star Inc.).

2.6. Lentivirus constructs

shRNA sequences targeting SMOC-2 (SMOC-2-shRNA-1: 5′-GCUG AAGAUGCUAGUCUAUA-3′, SMOC-2-shRNA-2: 5′-GUUGCUGAAGAGAAUGUAUA-3′, SMOC-2-shRNA-3: 5′-GACGGAAUAAUGACAAA-3′) and a negative control sequence (control: 5′-TTTCGGAAGTGTACG-3′) were synthesized and inserted into pGLVU6/Puro vector (GenePharma, Shanghai, China). Virus packaging was performed in 293 T cells using Lipofectamine 3000 (Invitrogen). Viruses were harvested at 72 h after transfection. The AN3CA cells (1 × 10⁵) were infected with the filtered lentivirus in the presence of 2 μg/ml puromycin (Sangon, Shanghai) and the silencing effects were verified by western blotting analysis.

2.7. Cell transfection

Cells were plated at 60–70% confluence in 60 mm dishes. AN3CA, Ishikawa and HEC-1A cells were transfected with si-SMOC-2 or with a non-targeted siRNA as a control. The sequences of the siRNA used were as follows: si-SMOC-2-1, GCUG AAGAUGCUAGUCUAUA; si-SMOC-2-2, GUUGCUGAAGAGAAUGUAUA; si-SMOC-2-3, GACGGAAUAAUGACAAA. The transfected cells were cultured in the presence of 2 μg/ml puromycin (Sangon, Shanghai) and the silencing effects were verified by western blotting analysis.

Fig. 1. SMOC-2 is a signature gene of endometrial cancer stem cells. (a) Flow cytometry analysis of CD133+/CD44+ and CD133−/CD44− cells sorted from AN3CA and Ishikawa. (b) The expression of SMOC2 in CD133+/CD44+ and CD133−/CD44− cells from AN3CA and Ishikawa was detected by western blotting and normalized by tubulin expression. (c) Relative mRNA expression levels of SMOC2 in AN3CA/CD133+/CD44+ and Ishikawa/CD133+/CD44+ cells compared with AN3CA/CD133−/CD44− and Ishikawa/CD133−/CD44− cells. (mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test). (d) Relative mRNA expression levels of SMOC2 in spherical cultures of AN3CA and Ishikawa cells compared with those in monolayer cultures. (mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test). (e) Silencing efficacy of SMOC-2 in AN3CA and Ishikawa cells was detected by real-time PCR. (f) Silencing efficacy of SMOC-2 in AN3CA and Ishikawa cells was detected by western blotting. (g) Sphere assay was performed with si-SMOC2-1, si-SMOC2-2 or siCt-transfected AN3CA and Ishikawa cells and passage cells. Scale bars, 50 μm. Quantification of sphere number was shown. (mean ± SD, * P < 0.05, ** P = 0.01, *** P = 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test). (h) The expression of SOX2, OCT4, and NANOG in SMOC-2-silenced cells AN3CA/Ishikawa were detected by western blotting. (i) Overexpression efficacy of SOX2 in HEC-1A and ECC-1 cells was determined by western blotting. (j) Overexpression efficacy of SMOC-2 in HEC-1A and ECC-1 cells was determined by western blotting.

2.8. Cell viability assay (CCK8 assay)

The cells were plated in 96-well plates at a density of 4000 cells per well with 100 μl of complete culture medium and cultured for 2–5 days. Each group contains five wells. 10 μl Cell Counting Kit-8 (CCK-8, WST-8, Dojindo, Japan) solution was added to each well after 48 h and 120 h. The cell cultures were sparse after 48 h or confluent after 120 h. CCK8 was metabolized to produce a colorimetric dye that was read at 450 nm using a microplate reader.

2.9. Western blotting

Total cellular protein and nuclear-cytosol protein were extracted using a total protein extraction buffer (Beyotime, China) and Nuclear-cytosol extraction kit (Applygen Technologies Inc. #1200). Cell lysates were separated by SDS-PAGE followed by blocking in 1% BSA (Bovine Serum Albumin), then incubated with primary antibodies against SMOC-2 (1:1000), β-catenin (1:1000), β-actin (1:2000), β-Tubulin (1:100000), Lamin A/C (1:1000) and species-specific secondary antibodies. Bound secondary antibodies were detected with the Odyssey imaging system (LI-COR Biosciences, Lincoln, NE).

2.10. RNA isolation and real-time qPCR

Total cellular RNA was extracted using Trizol reagent (Takara). PrimeScript RT-PCR kit (Takara) was used to perform the RT according to the protocol. SYBR Premix Ex Taq (Takara) on a 7500 real-time PCR system (Applied Biosystems) was used to determine the SMOC-2 mRNA expression at the following cycling settings: one initial cycle at 95 °C for 10 s followed by 40 cycles of 5 s at 95 °C and 31 s at 60 °C. Data were normalized to 18 s expression and represent the average of three repeated experiments. Prime sequences used for SMOC-2, MYC, CyclinD1, SOX2, OCT4, NANOG and 18 s detection are showed in Supplementary Table 2.

2.11. Immuno-fluorescence (IF)

We cultured the cells in 8-well chambers (Ibidi, Germany) for IF staining. The cells were fixed with 4% polyformaldehyde (15 min), permeabilized with 0.1% TritonX-100 (2 min) and blocked with 10% BSA (60 min) at room temperature. Cells were incubated with primary antibodies against β-catenin (1:200) at room temperature (60 min) then labeled with Alexa 488-conjugated secondary antibody (1:400) for 1 h at room temperature. The nuclei were counterstained for 2 min with DAPI (Sigma, USA). Images were acquired using confocal microscopy (LSM 510, META Laser Scanning Microscope, Zeiss).

2.12. In vivo tumor xenograft model

Six-week-old female athymic nude (nu/nu) mice (SLAC, Shanghai, China) were randomly divided into two groups and injected subcutaneously in the right flank with the stable single cell clones of AN3CA-sh1
and control cells at $5 \times 10^6$ cells in 100 μl serum-free DMEM medium for each nude mouse. After 6 weeks, mice were killed. The tumors were dissected and fixed with phosphate-buffered neutral formalin for standard histologic examination. Then paraffin embedded tumor samples were cut into 4-μm-thick sections for apoptosis detection. In situ tissue apoptosis was detected according to the protocol of TUNEL kit. Mice were manipulated and housed according to protocols approved by the East China Normal University Animal Care Commission.

2.13. Transcriptional reporter gene assay

SMOC-2 silenced cells and control cells were cultured in 96-well plates at a concentration of 7000 cells per well. 200 ng TCF Reporter Plasmid (WNT/β-catenin signaling), GLI Reporter Plasmid (Hedgehog signaling) or RBP-JK Reporter Plasmid (Notch signaling) (Millipore) and 10 ng pRL-TK (Renilla-TK-luciferase vector, Promega) were co-transfected into the cells. After 48 h, Dual-Glo Luciferase reporter Assay System (E1910, Promega) was used to measure the luciferase.
activities following the manufacturer’s instructions. The ratio of reporter plasmids was determined, each normalized to the luciferase activities of the Renilla-TK-luciferase vector.

2.14. Paclitaxel, cisplatin and XAV-939 treatment

The stock solution of paclitaxel and cisplatin were prepared in dimethyl sulfoxide (DMSO) at 1 mM and 50 mM. Cells were treated with 0.01 nM, 0.1 nM, 0.5 nM, 2.5 nM, 12.5 nM, 200 nM, 500 nM, 1000 nM paclitaxel and 0.1 μM, 0.5 μM, 2.5 μM, 12.5 μM, 50 μM, and 200 μM, 500 μM, 1000 μM cisplatin for 48 h. Drugs in the medium were replaced every 24 h. Control cells were incubated with the same volume of DMSO. Cells in the combined paclitaxel/cisplatin with XAV-939 treatment group were cultured in the presence of 5 μM XAV-939 and drugs for 48 h. For in vivo tumor xenograft, cisplatin (5 mg/kg) or normal saline were injected intraperitoneally once every 3 days.

2.15. Co-immunoprecipitation (CO-IP) assay and co-culture immunoprecipitation assay

For co-immunoprecipitation assay, AN3CA cell lysates transfected with Flag-tagged SMOC-2 or vector control were subjected to immunoprecipitation with Flag antibody (1:1000) or control IgG for 2 h at 4 °C. All immunoprecipitations were performed with protein A/G sepharose (Santa Cruz Biotechnology) on a spinning wheel at 4 °C overnight. The beads were collected by centrifugation at 3000 rpm, then washed three times with lysis buffer. The immunoprecipitates were subjected to WB.

For the co-culture IP assay, the plasmids of Fzd6-HA, LRP6-HA, Wnt3a-myc, and Wnt10b-myc were all purchased from Shanghai Generay Biotech Co., Ltd. HEK293T cells were cultured in 6-well plates and individually transfected with 0.5 μg expression plasmids for SMOC-2-Flag or WNT receptor expression plasmids: LRP6-HA or Fzd6-HA, ligand expression plasmids: Wnt3a-myc or Wnt10b-myc using Lipofectamine 3000. After 24 h of co-culture, cell lysates with Fzd6 or LR6 receptors and cell lysates with Wnt3a or Wnt10b ligands were prepared in a ratio of 1:2:2 to detect the interaction of one receptor (Fzd6 or LR6) and two ligands (Wnt3a and Wnt10b). The consequent steps were the same as the IP assay mentioned above. Membranes were probed using anti-HA (1:1000), anti-myc (1:1000), or anti-Flag (1:1000) monoclonal antibodies.

2.16. In situ proximity ligation assay

DuoLink PLA assay was performed to detect the interactions between SMOC-2 and LR6P/Fzd6 in stem cells and non-stem cells (DUO92102, Generay Biotech Co., Ltd. HEK293T cells were cultured in 6-well plates and individually transfected with 0.5 μg expression plasmids for SMOC-2-Flag or WNT receptor expression plasmids: LRP6-HA or Fzd6-HA, ligand expression plasmids: Wnt3a-myc or Wnt10b-myc using Lipofectamine 3000. After 24 h of co-culture, cell lysates with Fzd6 or LR6 receptors and cell lysates with Wnt3a or Wnt10b ligands were prepared in a ratio of 1:2:2 to detect the interaction of one receptor (Fzd6 or LR6) and two ligands (Wnt3a and Wnt10b). The consequent steps were the same as the IP assay mentioned above. Membranes were probed using anti-HA (1:1000), anti-myc (1:1000), or anti-Flag (1:1000) monoclonal antibodies.

2.17. Statistical analysis

Data are presented as means ± standard deviation (SD). Statistical analyses were done using GraphPad Prism 6 for windows. Chi-square test or student’s t-test were used to compare the results from different groups. The relationship between SMOC-2 expression and CSCs markers (CD133 and CD44) was analyzed using Chi-square test (χ² test) and Pearson’s correlation test. The relationship between SMOC-2 expression and nuclear localization of β-catenin was used Spearman correlation analysis. Values of P < 0.05 were considered statistically significant.

3. Results

3.1. SMOC-2 is a signature gene of endometrial cancer stem cells

To determine whether SMOC-2 is related to the CSCs of endometrial cancer, CD133+/CD44+ cells, which have been previously described as cells possessing CSC characteristics, were isolated from AN3CA and Ishikawa cells by flow cytometry. As shown in Fig. 1a, CD133+/CD44+ was heterogeneously expressed in tested endometrial cells, 1.57% in Ishikawa and 1.66% in ACSI CA cells. Then, we measured the SMOC-2 expression level in CD133+/CD44+ and CD133/CD44− cells by quantitative RT-PCR and western blotting. Our data revealed that SMOC-2 expression was much higher in sorted CD133+/CD44+ cells than that in CD133−/CD44− cells (Fig. 1b-c). It is well-known that CSCs have the ability to proliferate as spheres when cultured under non-adherent conditions [31]. Thus, we applied CSC-rich spheroids as a second model to confirm our results. Quantitative RT-PCR was conducted to analyze the SMOC-2 expression in AN3CA and Ishikawa cells grown either as monolayers or as spheres. The expression of SMOC-2 was significantly increased in spheres compared to monolayer cultures (Fig. 1d). We further investigated whether SMOC-2 have any effects on the clonogenic potential of endometrial cancer. The results showed that silencing of SMOC-2 greatly reduced the clonogenic potential of endometrial cancer by sphere assay in both primary and secondary sphere (Fig. 1e, f and g). Moreover, the expression of stemness-associated genes (SOX2, OCT4, NANOG) were downregulated in SMOC-2-silenced cells; overexpressioning of SMOC-2 upregulated the expression of SOX2, OCT4 and NANOG (Fig. 1h, i and Fig. S1a, 1b). These results collectively demonstrated that SMOC-2 might be a potential cancer stem cell marker for endometrial cancer.

3.2. SMOC-2 promotes endometrial cancer cell growth in vitro and in vivo

We further investigated whether SMOC-2 has any effect on the cell proliferation of endometrial cancer. The results showed that silencing SMOC-2 had no effect on the proliferation of cells grown at low density (sparse culture). However, interestingly, we found silencing SMOC-2

Table 1
Half maximal inhibitory concentration (IC50) of three groups cells treated with Paclitaxel or Cisplatin.

|          | Paclitaxel (nM) | Cisplatin (μM) |
|----------|----------------|----------------|
|          | AN3CA          | Ishikawa       |
| siCT     | 6.308          | 1.857          | 35.76 | 10.04 |
| siSMOC-2-1 | 2.404          | 0.5394         | 13.1  | 2.705 |
| siSMOC-2-2 | 1.05           | 0.2058         | 5.526 | 0.9221 |

Fig. 3. Silencing SMOC-2 enhanced paclitaxel and cisplatin sensitivity. (a) siCT, siSMOC-2-1, and siSMOC-2-2 groups of AN3CA and Ishikawa cells were treated with a series of concentrations paclitaxel/cisplatin to obtain half maximal inhibitory concentration (IC50). (b) Sphere assay was performed with vector, SMOC-2 DNA transfected HEC-1A and ECC-1 cells and SMOC-2 overexpressioning cells treated with paclitaxel or cisplatin. Scale bars, 50 μm. Quantification of sphere number was shown. (mean ± SD, **P < 0.01, ***P < 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test). (c) Morphologic characteristics of tumors from mice inoculated with sh-vector/Saline, sh-vector/Cisplatin, sh-SMOC-2/Saline and sh-SMOC-2/Cisplatin cells. (d) Tumor volumes of 4 groups from c. n = 5. (mean ± SD, **P < 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test). (e) TUNEL assay was detected in 4 groups from c. Scale bars, 50 μm. (mean ± SD, **P < 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test). (f) PCNA staining was detected in 4 groups from c. Scale bars, 50 μm. (mean ± SD, **P < 0.001. Experiments were statistically analyzed using two-tailed Student’s t-test).
significantly suppressed the proliferation of cells grown at high density (confluent culture) (Fig. 2a). Normally, cancer cells lose their contact inhibition, a phenomenon that restricts the in vitro growth of normal cells at confluence, so they still grow in confluent condition. Furthermore, we found that the overexpression of SMOCC-2 promoted cell proliferation in confluent culture but had no effect on cell proliferation in sparse monolayers (Fig. 2b). These data indicated that SMOCC-2 might confer endometrial cancer cells with the ability to overcome their contact inhibition.

To further confirm the effects of SMOCC-2 on endometrial cancer cell growth in vivo, stable cell lines were established that were transduced by the lentivirus carrying SMOCC-2-short hairpin RNA in endometrial cancer cells (Fig. S1c). Then, Lenti-sh-SMOC-2/AN3CA cells and Lenti-vector cells were inoculated subcutaneously into nude mice. The weight and size of the tumors formed by Lenti-sh-SMOC-2 cells were significantly decreased in comparison with the tumors formed by Lenti-vector cells. The average volume and weight of the tumors in Lenti-sh-SMOC-2 mice were 0.309 ± 0.079 cm³ and 0.329 ± 0.008 g in contrast to 0.554 ± 0.191 cm³ and 0.590 ± 0.176 g in control mice (P = 0.042 and 0.025). (Statistical analysis was performed by Student’s t-test) (Fig. 2c, d). In short, silencing SMOCC-2 in endometrial cancer cells suppressed cell growth at high density in vitro and reduced xenograft tumor growth in vivo.

3.3. SMOCC-2 enhances paclitaxel- and cisplatin-resistance in endometrial cancer cell

As chemotherapeutic resistance is another feature of CSCs, we next determined whether there is an association between SMOCC-2 expression and resistance to two chemotherapeutic agents, paclitaxel and cisplatin, in endometrial cancer. To this end, we treated SMOCC-2-silenced cells grown at high density with a series of concentrations paclitaxel or cisplatin. After 48 h treatment, cells survival rates were measured by CCK8 assay and half maximal inhibitory concentration (IC₅₀) of paclitaxel/cisplatin against cell survivability were analyzed. The results showed that IC₅₀ value of siSMOC-2 groups were less than siCT groups. Silencing SMOCC-2 enhanced the cytotoxic effects on AN3CA and Ishikawa cells (Fig. 3a and Table 1). Moreover, overexpression of SMOCC-2 reduced the cytotoxic effects on HEC-1A and ECC-1 cells in sphere assay (Fig. 3b). This result indicated that SMOCC-2 enhanced paclitaxel- and cisplatin-resistance.

To further confirm the results in vivo, Lenti-shSMOC-2/AN3CA cells or Lenti-vector cells were subcutaneously inoculated into nude mice. A few mice bearing subcutaneous tumors were treated with cisplatin (3 mg/kg per mouse) or saline once a week for four weeks (four injections in total) when the tumors first became palpable and lasted for 1 week. A significant reduction in the tumor weight and volume was recorded in the Lenti-shSMOC-2 group treated with saline compared to that in the Lenti-vector group treated with saline (P = 0.0004, P = 0.0011). Statistical analysis was performed by Student's t-test). Further, tumors derived from the Lenti-shSMOC-2 group treated with cisplatin were significantly smaller than those derived from Lenti-vector group treated with cisplatin (P < 0.0001). Statistical analysis was performed by Student's t-test (Fig. 3c–d). Apoptosis was significantly increased, and proliferation was suppressed in Lenti-shSMOC-2 tumors versus Lenti-vector tumors and cisplatin treated versus Lenti-vector tumors as detected by TUNEL assay and PCNA staining, respectively. Moreover, SMOCC-2 knockdown enhanced cisplatin-induced tumor cell apoptosis and anti-proliferation (Fig. 3e–f). Taken together, these data demonstrated that silencing SMOCC-2 enhanced paclitaxel and cisplatin sensitivity in endometrial cancer cells.

3.4. SMOCC-2 activates the WNT/β-catenin pathway

Having shown the effects of SMOCC-2 on endometrial cancer cell proliferation and chemoresistance, we next explored the mechanism by which SMOCC-2 alters the function of CSCs. It has been reported that related signaling pathways, such as WNT/β-catenin, Hedgehog and Notch, played essential roles in cancer stem cells. Here, we examined which pathway is involved in the function of SMOCC-2 in endometrial cancer cells using a dual-luciferase reporter gene assay. A WNT/β-catenin reporter plasmid (TCF/catenin plasmid), Hedgehog reporter plasmid (GLI plasmid), Notch reporter plasmid (RBPl plasmid) and Renilla were transfected into SMOCC-2 silencing cells AN3CA and HEC-1A. The results showed that WNT/β-catenin signaling was significantly inhibited in SMOCC-2 silenced groups, while the other signaling pathways experienced no significant change (Fig. 4a, Figs. S1d and S2a). We further confirmed that WNT/β-catenin signaling was activated by overexpressing SMOCC-2 (Fig. 4b and Fig. S1e). Moreover, the expression of downstream target genes of WNT/β-catenin signaling (cyclin-D1 and MYC) were downregulated in SMOCC-2-silenced cells compared with control cells (Fig. 4c). Immunofluorescence (IF) staining of β-catenin showed that the nuclear localization of β-catenin was more evident in SMOCC-2 over-expressing cells than that in control cells (Fig. 4d). Western blotting also showed nuclear β-catenin was significantly increased in SMOCC-2 over-expressing cells compared to that in control cells (Fig. 4e). Moreover, immunohistochemical staining of 151 endometrial cancer tissues also showed a positive association between SMOCC-2 expression and nuclear localization of β-catenin, R = 0.4266, P < 0.001 (Spearman correlation analysis) (Fig. 4f and Fig. S2b). To further illustrate that SMOCC-2 activates WNT/β-catenin signaling in endometrial cancer cells, XAV-939, a small molecule inhibitor of WNT/β-catenin signaling was used for further experiments. We treated HEC-1A and ECC-1 cells with XAV-939 and 50 nM paclitaxel or 1 μM cisplatin at the same time. The data showed that the overexpression of SMOCC-2 enhanced chemoresistance in both HEC-1A and ECC-1 cells. These effects were completely abrogated by XAV-939 (Fig. 4g). These results indicated that SMOCC-2 activates the WNT/β-catenin pathway by promoting the nuclear translocation of β-catenin. Obstructing the WNT/β-catenin signaling can reverse the effects of SMOCC-2 on endometrial cancer cell chemoresistance.

3.5. SMOCC-2 enhances ligand-receptor interaction of WNT/β-catenin pathway

Next, to investigate how the SMOCC-2 activate WNT/β-catenin pathway, we examined the interaction between SMOCC-2 and WNT proteins. Co-immunoprecipitation (CO-IP) results showed that SMOCC-2 had no direct interaction with the canonical WNT proteins (Wnt3a and
LRP1 and LRP7 (Fig. S3). We further investigated the molecular mechanism of SMO2-2 modulating the WNT ligand-receptor interaction. To this end, an interaction assay was performed, which was based on the immunoprecipitation of tagged proteins from the lysates of co-cultured HEK293T cells. Co-cultured HEK293T cells were transfected with the expression plasmids of SMO2-2-Flag, Fzd6-HA, LRPS-HA, Wnt3a-myc and Wnt10b-myc (co-culture IP) (Fig. 5b-e). Cell lysates were immunoprecipitated with an HA antibody and immunoblotted with anti-Flag, anti-HA or anti-Myc antibodies. As shown in Fig. 5b, Fzd6 can co-precipitate with SMO2-2, Wnt3a and Wnt10b, and SMO2-2 overexpression can enhance the binding between Wnt3a and Fzd6 (lanes 6 and 8). A similar enhancement of the WNT-FZD interaction by SMO2-2 was also observed in combinations of Wnt10b and Fzd6 (Fig. 5b, lanes 7 and 9). Next, the effect of SMO2-2 on the interaction between Wnt3a/Wnt10b and LRPS was examined. Similarly, SMO2-2 also enhanced the interaction between Wnt3a/Wnt10b and LRPS (Fig. 5d-e). Moreover, we tested if the interaction of SMO2-2 with Fzd6/LRPS occurs differently in stem versus non-stem cells. Duolink in situ proximity ligation assay showed that non-stem cells showed only a few PLA foci, whereas many PLA foci were found in stem cells (Fig. 5f). To further confirm that SMO2-2 directly interacted with Fzd6/LRPS in activating WNT/β-catenin pathway, we treated SMO2-2 overexpression cells with a series of concentrations paclitaxel or cisplatin and silenced Fzd6/ LRPS at the same time. The results showed that overexpression of SMO2-2 reduced the cytotoxic effects on both HEC-1A and ECC-1 cells. Silencing of Fzd6/LRPS reversed the chemoresistance effects of SMO2-2 on endometrial cancer cells (Fig. 5g). These results suggest that SMO2-2 directly interacted with Fzd6/LRPS and enhances the interaction between the canonical WNT ligands and receptors in endometrial cancer CSCs.

3.6. SMO2-2 and CSCs markers are co-expressed in endometrial cancer

To further evaluate whether SMO2-2 is a marker for CSCs in endometrial cancer, we investigated the expression level of SMO2-2, CD133 and CD44 in 151 endometrial cancer patients, and analyzed the relevance with clinicopathological parameters. The high expression rate of SMO2-2, CD133 and CD44 were 70.19%, 50.99% and 58.27%, respectively. The results also demonstrated that SMO2-2 expression correlated with pathological grade, depth of myometrial invasion and age (P = 0.000, 0.0469 and 0.0046, Statistical analysis was performed by Student's t-test) (Table 3). CD133 expression correlated with pathological grade, depth of myometrial invasion and vascular invasion while CD44 expression correlated with FIGO stage, pathological grade and lymph node metastasis (Tables 3-5). Moreover, based on the IHC staining, a positive correlation was found between the SMO2-2 expression and the CD133 expression (R = 0.4122, P < 0.0001, Pearson correlation analysis). The expression of SMO2-2 also had a positively correlation with the expression of CD44 (R = 0.4358, P < 0.0001, Pearson correlation analysis) (Table 6). Obviously, SMO2-2 expression was closely associated with risk factors of poor prognosis and CSC marker expression (Fig. 6).

4. Discussion

Cancer stem cells (CSCs) have distinct characteristics including self-renewal, drug resistance, and expression of specific markers that enable their isolation [32]. In endometrial cancer, it is still challenging to identify CSCs. A number of cell surface markers, including CD133, CD44, etc., can identify endometrial CSCs [20,21,33,34]. However, the markers of endometrial CSCs remain controversial. Here, we identified SMO2-2 as a novel signature gene of endometrial cancer stem cells. First, the expression of SMO2-2 was higher in CD133+/CD44+ cells than that in CD133−/CD44− cells. Second, SMO2-2 expression is greatly increased in spheres compared to monolayer cultures. Third, using the sphere assay, silencing SMO2-2 reduced the clonogenic potential of endometrial cancer cells and downregulated the expression of SOX2, OCT4, and NANOG, the stemness-associated genes. Fourth, SMO2-2 enhanced the chemoresistance of endometrial cancer cells. Fifth, immunohistochemical staining revealed that the expression of SMO2-2 was positively correlated with CD133 and CD44 expression in patient tissues. A previous study has also elaborately identified SMO2-2 as a colon cancer stem cell signature gene [28].

It has been reported that SMO2-2 executed its biological function through integrin-dependent signaling [35]. In this study, we demonstrated that SMO2-2 activated WNT/β-catenin signaling in endometrial cancer, which is supported by the following evidence. 1) Using the luciferase reporter assay system, it was revealed that overexpressing SMO2-2 promoted the activation of WNT/β-catenin signaling, while silencing SMO2-2 reduced the activation of WNT/β-catenin signaling. 2) Silencing SMO2-2 could significantly inhibit the expression of cyclinD1 and MYC, the important target genes of the WNT/β-catenin signaling. 3) Both western blotting and immunofluorescence staining revealed that overexpressing SMO2-2 significantly increased the nuclear translocation of β-catenin, which led to activate a downstream pathway. 4) It was discovered through CO-IP assay that SMO2-2 may bridge the Fzd6 and LRPS proteins through trimer formation, further enhancing Wnt ligand-receptor interactions. Therefore, we concluded that SMO2-2 may participate in the progression of endometrial cancer through the Wnt/β-catenin signaling pathway.

Table 2

| Paclitaxel (nM) | Cisplatin (μM) |
|---------------|---------------|
| AN3CA Ishikawa | AN3CA Ishikawa |
| Visa | 0.8369 | 2.404 | 11.69 | 8.978 |
| SMO2-2 | 19.3 | 28.79 | 123.8 | 156.3 |
| SMO2-2 + siLRP6 | 3.02 | 7.585 | 40.17 | 76.77 |
| SMO2-2 + siFzd6 | 8.123 | 10.32 | 27.52 | 23.09 |

Fig. 5. SMO2-2 enhances ligand-receptor interaction of WNT/β-catenin pathway. (a) Co-IP assay between SMO2-2 and canonical WNT components (ligand: Wnt3a or Wnt10b, receptor: Fzd6 or LRPS). AN3CA cells were transfected with SMO2-2-Flag or a control vector. The input on the right panel shows the levels of transfected Flag-SMO2-2 and endogenous WNT components (Wnt3a, Wnt10b, Fzd6 and LRPS) in Flag-tagged SMO2-2 or vector control. (b) SMO2-2 enhanced the binding between canonical WNT protein (Wnt3a or Wnt10b) and Fzd6. Ha-tagged Fzd6-expressing cells were co-cultured with Myc-tagged WNT ligand-expressing (Wnt3a or Wnt10b) cells and Flag-tagged SMO2-2 expressing cells both separately and in combination. The Ha-tagged Fzd6 was immunoprecipitated in this experiment. (c and d) Densitometric analysis showed the relative amounts of precipitated WNT ligand (Wnt3a or Wnt10b) interacted with Fzd6 or LRPS affected by SMO2-2. Values are normalized to intensities without SMO2-2 as 1. (e) SMO2-2 enhanced the binding between the canonical WNT protein (Wnt3a or Wnt10b) and LRPS. Similarly, Ha-tagged LRPS-expressing cells were co-cultured with WNT ligands-expressing cells and Flag-tagged SMO2-2-expressing cells both separately and in combination. The interactions of SMO2-2 and LRPS/Fzd6 were detected by in situ proximity ligation assay (red dots, n = 3, mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.0001. Experiments were statistically analyzed using two-tailed Student's t-test). Scale bars: 20 μm. (g, Vector, SMO2-2, SMO2-2 + siLRP6 and SMO2-2 + siFzd6 groups of HEC-1A and ECC-1 cells were treated with a series of concentrations paclitaxel/cisplatin to obtain half maximal inhibitory concentration (IC50).
The Wnt/β-catenin signaling pathway has a crucial function in cell proliferation, differentiation, growth, survival, development and fate determination in adult organisms [36]. Moreover, Wnt signaling supports the formation and maintenance of stem and cancer stem cells [37]. In the intestine, downstream of Wnt/β-catenin, the Tcf4-driven target gene program is essential to maintain intestinal crypt stem cells [38]. In the mammary gland, a Wnt ligand, Wnt3a, functions as a rate-limiting, self-renewal factor to clonally expand mammary stem cells [38]. In endometrial cancer, targeting Wnt signaling inhibited the proliferation, migration, invasiveness and tumorigenicity of endometrial cancer stem cells [45]. Our findings identify the extracellular matrix protein SMOC-2 as a unique signaling node that drives self-renewal and therapeutic resistance through the Wnt/β-catenin signal pathway, which provides novel evidence for targeting Wnt signaling in endometrial cancer.

Our study revealed that SMOC-2 may be a stem cell signature gene in endometrial cancer, and we discovered a novel regulator of WNT/β-catenin signaling. However, a key limitation of this study is that we only examined the biological functions of SMOC-2 in an in vitro cell model and xenograft mouse model. We are establishing a patient-derived xenograft (PDX) model and genetically engineered mice for further studies.

In conclusion, SMOC-2 is a cancer stem cell-associated matricellular protein in endometrial cancer and promoted cell proliferation, enhanced resistance toward chemotherapy both in vitro and in vivo. This effect was associated with the activation of WNT/β-catenin signaling. These findings suggest that the SMOC-2-Wnt/β-catenin axis may be a novel target for endometrial cancer therapy.

### Table 3
Correlation of SMOC-2 expression with patient’s clinical characteristics.

| SMOC-2 | Total | X² | P   |
|--------|-------|----|-----|
| High   | Low   |     |     |
| FIGO stage |       |     |     |
| I      | 66 (64.71%) | 36 (35.29%) | 102 | 4.64 | 0.098 |
| II     | 15 (78.95%) | 4 (21.05%) | 19  |     |      |
| III + IV | 25 (83.33%) | 5 (16.67%) | 30  |     |      |
| Grade  |       |     |     |
| 1      | 14 (43.75%) | 18 (56.25%) | 32  | 16.212 | 0.000 |
| 2      | 47 (71.21%) | 19 (28.79%) | 66  |     |      |
| 3      | 45 (84.91%) | 8 (15.09%)  | 53  |     |      |
| Depth of Myometrial Invasion ≤ 50% | 52 (63.41%) | 30 (36.59%) | 82  | 3.948 | 0.0469 |
| > 50%  | 54 (72.26%) | 15 (27.74%) | 69  |     |      |
| Lymph node metastasis Present | 16 (80%) | 4 (20%) | 20 | 1.059 | 0.3035 |
| Absent | 90 (68.71%) | 41 (31.29%) | 131 |     |      |
| Vascular Invasion Present | 20 (76.92%) | 6 (23.08%) | 26  | 0.5824 | 0.4454 |
| Absent | 86 (68.8%) | 39 (31.2%) | 125 |     |      |
| Age ≤ 60 y | 59 (62.11%) | 36 (37.89%) | 95  | 8.021 | 0.0046 |
| > 60 y | 47 (83.93%) | 9 (16.07%) | 56  |     |      |

### Table 4
Correlation of CD133 expression with patient’s clinical characteristics.

| CD133 | Total | X² | P   |
|-------|-------|----|-----|
| High  | Low   |     |     |
| FIGO stage |       |     |     |
| I      | 51 (50%) | 51 (50%) | 102  | 0.527 | 0.769 |
| II     | 9 (47.4%) | 10 (52.6%) | 19  |     |      |
| III + IV | 17 (56.67%) | 13 (43.33%) | 30  |     |      |
| Grade  |       |     |     |
| 1      | 7 (21.88%) | 25 (78.12%) | 32  | 20.115 | 0.000 |
| 2      | 32 (48.49%) | 34 (51.51%) | 66  |     |      |
| 3      | 38 (71.69%) | 15 (28.31%) | 53  |     |      |
| Depth of Myometrial Invasion ≤ 50% | 35 (42.68%) | 47 (57.32%) | 82  | 4.959 | 0.0260 |
| > 50%  | 42 (60.87%) | 27 (39.13%) | 69  |     |      |
| Lymph node metastasis Present | 11 (55%) | 9 (45%) | 20  | 0.1481 | 0.7004 |
| Absent | 66 (50.38%) | 65 (49.62%) | 131 |     |      |
| Vascular Invasion Present | 18 (69.23%) | 8 (30.77%) | 26  | 4.180 | 0.0409 |
| Absent | 59 (47.2%) | 66 (52.8%) | 125 |     |      |
| Age ≤ 60 y | 50 (52.63%) | 45 (47.37%) | 95  | 0.6231 | 0.4999 |
| > 60 y | 27 (48.21%) | 29 (51.79%) | 56  |     |      |

### Table 5
Correlation of CD44 expression with patient’s clinical characteristics.

| CD44 | Total | X² | P   |
|------|-------|----|-----|
| High  | Low   |     |     |
| FIGO stage |       |     |     |
| I      | 52 (50.98%) | 50 (49.02%) | 102  | 8.242 | 0.016 |
| II     | 12 (63.16%) | 7 (36.84%) | 19  |     |      |
| III + IV | 24 (80%) | 6 (20%) | 30  |     |      |
| Grade  |       |     |     |
| 1      | 7 (21.88%) | 25 (78.13%) | 32  | 24.285 | 0.000 |
| 2      | 41 (62.12%) | 25 (37.88%) | 66  |     |      |
| 3      | 40 (75.47%) | 13 (24.53%) | 53  |     |      |
| Depth of Myometrial Invasion ≤50% | 42 (51.22%) | 40 (48.78%) | 82  | 0.5968 | 0.4398 |
| >50%  | 46 (66.67%) | 23 (33.33%) | 69  |     |      |
| Lymph node metastasis Present | 17 (85%) | 3 (15%) | 20  | 6.770 | 0.0093 |
| Absent | 71 (54.19%) | 60 (45.81%) | 131 |     |      |
| Vascular Invasion Present | 16 (61.54%) | 10 (38.46%) | 26  | 0.1373 | 0.7110 |
| Absent | 72 (57.6%) | 53 (42.32%) | 125 |     |      |
| Age ≤ 60 y | 53 (55.79%) | 42 (44.21%) | 95  | 0.6525 | 0.4192 |
| > 60 y | 35 (62.3%) | 21 (37.7%) | 56  |     |      |

### Table 6
The association between SMOC-2, CD133 and CD44 expression.

| Total | SMOC-2 expression n = 151 | R² | P-Valueb |
|-------|--------------------------|----|---------|
| CD133 | High (%) | Low (%) |     |        |
| Low    | 74 | 33 (44.59) | 41 (55.41) | 0.4122 | 0.000 |
| High   | 77 | 73 (94.51) | 4 (5.49) |      |      |
| CD44   | Low (%) | High (%) |     |        |
| Low    | 63 | 29 (46.03) | 34 (53.97) | 0.4358 | 0.000 |
| High   | 88 | 77 (87.5) | 11 (12.5) |      |      |

a Values evaluated by the Pearson correlation analysis.
b Evaluated by X² test.
Negative expression of SMOC-2

SMOC-2

CD133

CD44

Positive expression of SMOC-2

Fig. 6. SMOC-2 and CSCs markers are co-expressed in endometrial cancer. 151 endometrial cancer tissues were stained with SMOC-2, CD44 and CD133 antibodies using serial sections. The left images represented a typical case of low expression of SMOC-2, and CD44 and CD133. The right images represented a typical case with high expression of SMOC-2, CD44 and CD133. Scale bars, 100 μm.

Acknowledgments

Not applicable.

Funding sources

This work was supported by the National Natural Science Foundation of China [grant numbers 81472445 and 81672587 to R. Zhang], the Scientific and Technological Innovation Act Program of Shanghai Science and Technology Commission (grant number 14411973100 to R. Zhang) and the Scientific and Technological Innovation Act Program of Fengxian Science and Technology Commission (grant number 20160908 to H. Lu), the Natural Science Foundation of Shanghai (17ZR1428300 to J. Li).

Declaration of interest

The authors declare no conflict of interest.

Author contributions

H.L. and DD.J. performed the in vitro experiments and wrote the original manuscripts. R.Z. and Z.G.Z supervised the experimental work and were involved in the analysis of the experimental data and the preparation of the manuscript. G.D.Y. and L.Y.Z. conducted the in vivo tumor formation assay. W.W.S., J.H. W and C.C.Z. performed the rest of the experiments. J.L. and X.M.Y. revised manuscripts. All authors contributed to the discussion and approved the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.12.044.

References

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87–108.

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017. https://doi.org/10.3322/caac.21387.

[3] Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497(7447):67–73.

[4] Church DN, Stellino E, Nout RA, Valcicova N, Depreeuw J, ter Haar N, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015;107(1):402.

[5] Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000;89(8):1758–64.

[6] Lax SF, Kendell B, Tashiro H, Siebos RJ, Ellenson LH. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinomas—Evidence of distinct molecular genetic pathways. Cancer 2000;88(4):814–24.

[7] Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jokseth J, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk: [PORT-EC-2]: An open-label, non-inferiority, randomised trial. Lancet 2010;376(9727):816–23.

[8] Group AES, Blake P, Swart AM, Orton J, Kirchner H, Whelan T, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review, and meta-analysis. Lancet 2009;373(9658):137–46.

[9] Mihm M, Gangooly S, Mutukrishna S. The normal menstrual cycle in women. Anim Reprod Sci 2011;124(3–4):229–36.

[10] Gargett CE, Nguyen HP, Ye L. Endometrial regeneration and endometrial stem/progenitor cells. Rev Endocr Metab Disord 2012;13(4):235–51.

[11] Gargett CE. Uterine stem cells: What is the evidence? Hum Reprod Update 2007;13(1):87–101.

[12] Gargett CE, Chan RW, Schwabe KE. Hormone and growth factor signaling in endometrial renewal. Role of stem/progenitor cells. Mol Cell Endocrinol 2008;288(1–2):22–9.

[13] Valentin A, Palal A, Al-Lamee H, Tempnest N, Drury J, Von Zglinicki T, et al. SSEA-1 isolates human endometrial basal glandular epithelial cells: Phenotypic and functional characterization and implications in the pathogenesis of endometriosis. Hum Reprod 2013;28(10):2095–708.

[14] Hubbard SA, Friel AM, Kumsara R, Zhang L, Rueda BR, Gargett CE. Evidence for cancer stem cells in human endometrial cancer. Cancer Res 2009;69(21):8241–8.

[15] Miller SJ, Lavker RM, Sun TT. Interpreting epithelial cancer biology in the context of stem cells: Tumor properties and therapeutic implications. Biochim Biophys Acta 2005;1756(1):25–52.

[16] Nagaraj AB, Joseph P, Koivakoski O, Singh S, Armstrong A, Redline R, et al. Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget 2015;6(27):23720–34.

[17] Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, et al. Cisplatin induces stemness in ovarian cancer. Oncotarget 2016;7(21):30511–22.

[18] Wan J, Gao Y, Zeng K, Xia Y, Zhao M, Wei J, et al. The levels of the sex hormones are not different between type 1 and type 2 endometrial cancer. Sci Rep 2016;6:39744.

[19] Lax SF. Pathology of Endometrial Carcinoma. Adv Exp Med Biol 2017;943:75–96.

[20] Mizuk D, Britten M, Allison M. CD133: Molecule of the moment. J Pathol 2008;214(1):1–9.
[21] Mirantes C, Espinosa I, Ferrer I, Dolcet X, Prat J, Matias-Guiu X. Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol 2013;44(10):1973–81.

[22] Kiyohara MH, Dillard C, Tsui J, Kim SR, Lu J, Sachdev D, et al. EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 2017;36(42):5793–807.

[23] Pazin DR, Abrecht KH. Developmental expression of Smoc1 and Smoc2 suggests potential roles in fetal gonad and reproductive tract differentiation. Dev Dyn 2009;238(11):2877–90.

[24] Rocnik EF, Liu P, Sato K, Walsh K, Vaziri C. The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity. J Biol Chem 2006;281(32):22855–64.

[25] Christian Vannahme SG, Paulsson Mats, Maurer Patrik, Hartmann Ursula. Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochem J 2003(373):805–14.

[26] Nishimoto SHY, Toda Y, Toyoda H, Kitamura K, Komurasaki T. Identification of a novel smooth muscle associated protein, smap2, upregulated during neointima formation in a rat carotid endarterectomy model. Biochim Biophys Acta 2002;1576(1–2):225–30.

[27] Maier S, Paulsson M, Hartmann U. The widely expressed extracellular matrix protein SMOC-2 promotes keratinocyte attachment and migration. Exp Cell Res 2008;314(13):2477–87.

[28] Shvab A, Haase G, Ben-Shmuel A, Gavert N, Brabletz T, Dedhar S, et al. Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression. Oncogene 2006;35(5):540–57.

[29] Schatton T, Murphy GF, Frank NY, Yanamura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature 2008;451(7176):345–9.

[30] Patrizia C, Ylenia L, Maria GF, Sebastino B, Matilde B, Giorgio S. Isolation and culture of colon cancer stem cells. Method Cell Biol 2008;85:311–24.

[31] Zhou J, Zhang Y. Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle 2008;7(10):1360–70.

[32] Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells: perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66(19):9339–44.

[33] Rutella S, Bonanno G, Crocchi A, Mariotti A, Corallo M, Prisco MG, et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial cancers. Clin Cancer Res 2009;15(13):4299–311.

[34] Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thagrarjjan PS, et al. CD55 regulates self-renewal and cisplatin resistance in endometrial tumors. J Exp Med 2017;214(9):2715–32.

[35] Peijun Liu JL, Wellington V, Cardoso, and cyrus vaziri. The SPARC-related factor SMOC-2 promotes growth factor-induced cyclin D1 expression and DNA synthesis via integrin-linked kinase. Mol Biol Cell 2008;19(1):248–61.

[36] Shi J, Chi S, Xue J, Yang J, Li P, Liu X. Emerging role and therapeutic implication of Wnt signaling pathways in autoimmune diseases. J Immunol Res 2016;2016:9392132.

[37] Peter Wend JDH, Ulrike ZIEBOLD, Walter BIRCHMEIER. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010;21:855–63.

[38] Grigoryan TWP, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: Conditional loss- and gain-of-function mutations of beta-catenin in mice. Gene Dev 2008;22:2308–41.

[39] Zeng YANR. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 2010;6:568–77.

[40] Polakis P. Wnt signaling and cancer. Genes Dev 2000;14(15):1837–51.

[41] O’Brien CAPA, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106–10.

[42] Sangiorgi ECM. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008;40:915–20.

[43] Sreekumar A, Toneff MJ, Toh E, Roarty K, Creighton CJ, Belka GK, et al. WNT-mediated regulation of FOXO1 constitutes a critical axis maintaining puerperal mammary stem cell homeostasis. Dev Cell 2017;43(4):436–48 [e6].

[44] Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007;446(7136):676–9.

[45] Kusunoki S, Kato K, Tabu K, Inagaki T, Okabe H, Kanaeda H, et al. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol 2013;129(1):598–605.